| 期 |
栏目 |
标题 |
文件 |
| 卷 16, 编号 1 (2019) |
Articles |
The role of ß2-adrenergic receptor gene polymorphisms in the pharmacological response to bronchial asthma therapy |
(Rus)
|
| 卷 15, 编号 4 (2018) |
Articles |
Federal Clinical Recommendations. Allergic rhinitis |
|
| 卷 14, 编号 4-5 (2017) |
Articles |
ACTUAL CONCEPTION OF ALLERGEN-SPECIFIC IMMUNOTHERAPY MECHANISMS, POTENTIAL BIOMARKERS OF EFFICACY AND WAYS OF ENHANCEMENT |
|
| 卷 11, 编号 1 (2014) |
Articles |
Skin care as a way to recover microbiome in patients with atopic dermatitis |
|
| 卷 16, 编号 2 (2019) |
Articles |
The response variability of the asthma patients to the standard pharmacotherapy |
(Rus)
|
| 卷 16, 编号 2 (2019) |
Articles |
Retention adherence to therapy as a guarantee of the SLIT efficacy |
(Rus)
|
| 卷 17, 编号 3 (2020) |
Reviews |
Non-steroidal anti-inflammatory drugs (NSAIDs) – exacerbated respiratory disease: epidemiology, pathogenesis, clinical findings and management |
(Rus)
|
| 卷 18, 编号 1 (2021) |
Letters to the editor |
Chronic urticaria in theory and practice. Experience of UCARE-centers for clinicians |
(Rus)
(Eng)
|
| 卷 19, 编号 1 (2022) |
Clinical practice guidelines |
Allergic rhinitis |
(Rus)
|
| 卷 19, 编号 2 (2022) |
Original studies |
Omalizumab in the severe exacerbations of seasonal allergic rhinitis |
(Rus)
(Eng)
|
| 卷 19, 编号 2 (2022) |
Reviews |
Allergen-specific immunotherapy and real-world evidence |
(Rus)
|
| 卷 19, 编号 2 (2022) |
Reviews |
Combination therapy of allergic rhinitis: efficacy, safety and impact on quality of life |
(Rus)
|
| 卷 19, 编号 3 (2022) |
Reviews |
Molecular allergology place in allergen-specific immunotherapy |
|
| 卷 20, 编号 2 (2023) |
Reviews |
Searching for predictive biomarkers of allergen-specific immunotherapy efficacy based on modern concepts of its mechanisms |
(Rus)
(Eng)
|
| 卷 21, 编号 1 (2024) |
Short communications |
Potential of the domestic biosimile omalizumab in achievement of control in patients with severe asthma: short communication |
(Rus)
|
